Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trifluridine/tipiracil + Anlotinib in 2L ESCC
NCT07142421Phase 2Active, not recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Aug 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil and anlotinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Progression-Free Survival at 24 months. Started Aug 2025; status: active, not recruiting.
02
Drugs
trifluridine + tipiracilanlotinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07142421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07142421.